Synthesis, Characterization and in vitro Anti-Tumoral Evaluation of Erlotinib-PCEC Nanoparticles

被引:18
作者
Barghi, Leila [1 ,2 ]
Asgari, Davoud [1 ]
Barar, Jaleh [1 ,3 ]
Nakhlband, Aylar [3 ]
Valizadeh, Hadi [1 ]
机构
[1] Tabriz Univ Med Sci, Fac Pharm, Tabriz, Iran
[2] Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran
[3] Tabriz Univ Med Sci, Res Ctr Pharmaceut Nanotechnol, Tabriz, Iran
关键词
Erlotinib; PCEC; solvent displacement method; nanoparticles; SHELL TYPE NANOPARTICLES; DRUG-RELEASE BEHAVIORS; CELL LUNG-CANCER; BIODEGRADABLE POLYMERS; TRIBLOCK COPOLYMER; TARGETED DELIVERY; MICROSPHERES; NANOSPHERES; POLY(EPSILON-CAPROLACTONE); PACLITAXEL;
D O I
10.7314/APJCP.2014.15.23.10281
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Development of a nanosized polymeric delivery system for erlotinib was the main objective of this research. Materials and Methods: Poly caprolactone-polyethylene glycol-polycaprolactone (PCEC) copolymers with different compositions were synthesized via ring opening polymerization. Formation of triblock copolymers was confirmed by HNMR as well as FT-IR. Erlotinib loaded nanoparticles were prepared by means of synthesized copolymers with solvent displacement method. Results: Physicochemical properties of obtained polymeric nanoparticles were dependent on composition of used copolymers. Size of particles was decreased with decreasing the PCL/PEG molar ratio in used copolymers. Encapsulation efficiency of prepared formulations was declined by decreasing their particle size. Drug release behavior from the prepared nanoparticles exhibited a sustained pattern without a burst release. From the release profiles, it can be found that erlotinib release rate from polymeric nanoparticles is decreased by increase of CL/PEG molar ratio of prepared block copolymers. Based on MTT assay results, cell growth inhibition of erlotinib has a dose and time dependent pattern. After 72 hours of exposure, the 50% inhibitory concentration (IC50) of erlotinib hydrochloride was appeared to be 14.8 mu M. Conclusions: From the obtained results, it can be concluded that the prepared PCEC nanoparticles in this study might have the potential to be considered as delivery system for erlotinib.
引用
收藏
页码:10281 / 10287
页数:7
相关论文
共 48 条
  • [31] A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva®, OSI-774) in patients with advanced solid tumors of epithelial origin
    Ranson, M.
    Shaw, H.
    Wolf, J.
    Hamilton, M.
    McCarthy, S.
    Dean, E.
    Reid, A.
    Judson, I.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (01) : 53 - 58
  • [32] Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles
    Reis, Catarina Pinto
    Neufeld, Ronald J.
    Ribeiro, Antonio J.
    Veiga, Francisco
    [J]. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2006, 2 (01) : 8 - 21
  • [33] Clonazepam release from core-shell type nanoparticles of poly(ε-caprolactone)/poly(ethylene glycol)/poly(ε-caprolactone) triblock copolymers
    Ryu, JG
    Jeong, YI
    Kim, IS
    Lee, JH
    Nah, JW
    Kim, SH
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 200 (02) : 231 - 242
  • [34] Ryu JG, 2001, B KOR CHEM SOC, V22, P467
  • [35] DEVELOPMENT OF BIODEGRADABLE MICROSPHERES AND NANOSPHERES FOR THE CONTROLLED-RELEASE OF CYCLOSPORINE-A
    SANCHEZ, A
    VILAJATO, JL
    ALONSO, MJ
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1993, 99 (2-3) : 263 - 273
  • [36] Poly(ethylene oxide)-modified poly(ε-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer
    Shenoy, DB
    Amiji, MA
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2005, 293 (1-2) : 261 - 270
  • [37] Poly-ε-caprolactone microspheres and nanospheres:: an overview
    Sinha, VR
    Bansal, K
    Kaushik, R
    Kumria, R
    Trehan, A
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 278 (01) : 1 - 23
  • [38] Erlotinib: Small-molecule targeted therapy in the treatment of non-small-cell lung cancer
    Smith, J
    [J]. CLINICAL THERAPEUTICS, 2005, 27 (10) : 1513 - 1534
  • [39] Biodegradable polymeric nanoparticles as drug delivery devices
    Soppimath, KS
    Aminabhavi, TM
    Kulkarni, AR
    Rudzinski, WE
    [J]. JOURNAL OF CONTROLLED RELEASE, 2001, 70 (1-2) : 1 - 20
  • [40] Targeted pharmaceutical nanocarriers for cancer therapy and Imaging
    Torchilin, Vladimir P.
    [J]. AAPS JOURNAL, 2007, 9 (02) : E128 - E147